Maruyama Y, Kryscio R, Van Nagell J R, Yoneda J, Donaldson E, Hanson M, Beach J L, Feola J M, Martin A, Parker C
Int J Radiat Oncol Biol Phys. 1985 Aug;11(8):1475-82. doi: 10.1016/0360-3016(85)90335-9.
252Cf, a neutron emitting radioactive transplutonium isotope, was tested for its efficacy against advanced bulky Stage III-IV cancers of the cervix in a clinical trial at the University of Kentucky Medical Center. Eighty-two patients were treated during 1976-1979 and followed for 5-year survival and tumor control. Three different treatment methods went on sequentially and concurrently, that is, (a) conventional whole pelvis photon with delayed 137Cs implants, (b) conventional photon therapy with delayed 252Cf implants, and (c) 252Cf implants ("early") preceding photon therapy. There were 12% 5-year survival for Stage IIIB cancers by conventional therapy, and 15% by delayed 252Cf implant therapy. For early 252Cf implant therapy there were 54% 5-year survivals with 4% complications and 65% 5-year local control, but distant metastases became a prominent delayed failure pattern.
252Cf是一种发射中子的放射性超钚同位素，肯塔基大学医学中心在一项针对晚期III - IV期宫颈癌的临床试验中，对其疗效进行了测试。1976年至1979年期间，对82名患者进行了治疗，并对其进行了5年生存率和肿瘤控制情况的随访。三种不同的治疗方法先后或同时进行，即：(a) 采用延迟137Cs植入的传统全盆腔光子治疗，(b) 采用延迟252Cf植入的传统光子治疗，以及(c) 在光子治疗之前进行的（“早期”）252Cf植入。对于IIIB期癌症，传统疗法的5年生存率为12%，延迟252Cf植入疗法的5年生存率为15%。对于早期252Cf植入疗法，5年生存率为54%，并发症发生率为4%，局部控制率为65%，但远处转移成为一种显著的延迟失败模式。
